www.fdanews.com/articles/74204-roche-and-ge-explore-personalized-medicine
ROCHE AND GE EXPLORE PERSONALIZED MEDICINE
July 12, 2005
Roche and GE Healthcare, a division of the General Electric Company, today announced a collaboration aimed at developing personalized care for patients with Alzheimer's disease. In controlled clinical trials, patients taking a Roche anti-amyloid drug candidate for Alzheimer's disease will be monitored clinically for drug response using GE's positron emission tomography (PET) diagnostic imaging agent. This proprietary PET technology measures and tracks levels of beta-amyloid, a form of brain plaque believed to cause memory loss in Alzheimer's disease patients. Previously, the presence of plaque could only be confirmed during autopsy.